MiMedx Group (NASDAQ:MDXG) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a sell rating in a report issued on Saturday.

A number of other research analysts have also commented on MDXG. Craig Hallum lowered their price target on MiMedx Group from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Weiss Ratings cut MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, Citizens Jmp cut their price objective on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Thursday, April 30th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, MiMedx Group presently has an average rating of “Moderate Buy” and an average price target of $8.50.

MiMedx Group Price Performance

MDXG stock opened at $4.13 on Friday. The firm’s 50-day moving average price is $3.92 and its two-hundred day moving average price is $4.24. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.99. The stock has a market capitalization of $601.99 million, a price-to-earnings ratio of 103.28 and a beta of 1.45. The company has a current ratio of 5.33, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. As a group, equities analysts predict that MiMedx Group will post -0.09 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its holdings in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after buying an additional 13,629 shares during the period. AQR Capital Management LLC boosted its position in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after acquiring an additional 4,296 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of MiMedx Group during the 1st quarter worth approximately $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares during the period. Finally, Millennium Management LLC raised its position in shares of MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after acquiring an additional 596,016 shares in the last quarter. Institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.